{
    "data": [
        {
            "id": "4476798",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-25T14:59:24-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1155689376/image_1155689376.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Revisiting A Stellar Grower",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "354376",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4476798-global-blood-therapeutics-stellar-grower"
            }
        },
        {
            "id": "4476695",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-24T04:12:27-05:00",
                "isLockedPro": false,
                "commentCount": 77,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1239854276/image_1239854276.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Status As The 'Pandemic Exterminator' Makes Them A Favorite For 2022",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105950",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "354246",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4476695-pfizer-pfe-pandemic-exterminator-2022-favorite"
            }
        },
        {
            "id": "4476361",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-22T09:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1229555002/image_1229555002.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Stock Forecast For 2022: What To Consider Going Forward",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "353855",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4476361-pfizer-stock-forecast-2022"
            }
        },
        {
            "id": "4476303",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-21T16:44:38-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1287045622/image_1287045622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merger Arbitrage Mondays: Pfizer Acquires Arena Pharmaceuticals At A 100% Premium",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "353741",
                            "type": "sentiment"
                        },
                        {
                            "id": "353742",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4476303-merger-arbitrage-mondays-pfizer-acquires-arena-pharmaceuticals-at-a-100-percent-premium"
            }
        },
        {
            "id": "4475793",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-17T16:07:20-05:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277088083/image_1277088083.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Cash Rich Pfizer Splashing $7 Billion On Arena Acquisition Makes Sense - Here's Why",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "353827",
                            "type": "sentiment"
                        },
                        {
                            "id": "353452",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4475793-pfizer-arena-acquisition-makes-sense"
            }
        },
        {
            "id": "4475334",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-15T08:42:00-05:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303673683/image_1303673683.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Paxlovid Holds Up",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "353156",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4475334-pfizers-paxlovid-holds-up"
            }
        },
        {
            "id": "4474091",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-08T11:56:33-05:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1131418344/image_1131418344.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Is Making A Fortune From COVID - Objective Valuation Implies Strong Upside Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "352311",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4474091-pfizer-stock-making-fortune-covid-valuation-upside"
            }
        },
        {
            "id": "4472972",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-02T07:01:28-05:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288428941/image_1288428941.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's One-Two-Punch Against COVID",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "351463",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4472972-pfizer-stock-new-covid-vaccine"
            }
        },
        {
            "id": "4472638",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-30T16:14:00-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1266993064/image_1266993064.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "IBI Research On Global Blood Therapeutics: Galvanized For Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "351162",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4472638-global-blood-therapeutics-gbt-stock-galvanized-for-growth"
            }
        },
        {
            "id": "4472461",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-30T10:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 120,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1298788278/image_1298788278.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Novavax Vs. Pfizer Stock: Which Is The Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "351027",
                            "type": "sentiment"
                        },
                        {
                            "id": "351028",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4472461-novavax-vs-pfizer-stock"
            }
        },
        {
            "id": "4472096",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-26T21:49:11-05:00",
                "isLockedPro": false,
                "commentCount": 92,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182745918/image_182745918.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Stock May Break Out On New COVID Variant",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22742",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "350813",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4472096-pfizer-ready-to-break-out"
            }
        },
        {
            "id": "4471284",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-23T07:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303457428/image_1303457428.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pandemic Winner Pfizer Is About To Have Its Best Year Ever Due To COVID",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "350252",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4471284-pandemic-winner-pfizer-is-about-to-have-its-best-year-ever-due-to-covid"
            }
        },
        {
            "id": "4471183",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-22T10:49:50-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "After Landmark COVID-19 Vaccine Success, Pfizer Looks To The Next Frontier",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106411",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "350269",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4471183-after-landmark-covidminus-19-vaccine-success-pfizer-looks-to-next-frontier"
            }
        },
        {
            "id": "4468854",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-12T08:26:08-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1312985523/image_1312985523.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's Premier COVID Franchise Lays The Foundation For Continued Outsized Returns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105950",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "348875",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4468854-pfizers-covid-franchise-lays-foundation-for-outsized-returns"
            }
        },
        {
            "id": "4468027",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-10T15:21:58-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440976/image_1292440976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Stock: How Will Recent Earnings Results Impact The Stock Going Forward",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "348609",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4468027-pfizer-stock-recent-earnings"
            }
        },
        {
            "id": "4467765",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-10T09:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440976/image_1292440976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Outlook For Pfizer Stock: A COVID-19 Pill And Children's Vaccines",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59101",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "348305",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4467765-pfizer-stock-outlook"
            }
        },
        {
            "id": "4467122",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-08T21:27:19-05:00",
                "isLockedPro": false,
                "commentCount": 114,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1207501947/image_1207501947.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Antiviral News Fallout - Implications For Other Oral Antivirals Including Molnupiravir",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104723",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "348232",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4467122-pfizer-antiviral-news-fallout-implications-for-other-oral-antivirals-including-molnupiravir"
            }
        },
        {
            "id": "4465966",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-05T11:50:01-04:00",
                "isLockedPro": false,
                "commentCount": 118,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1296011341/image_1296011341.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's COVID Pill Shows Vaccine Profits Will Be Fleeting",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24281",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "347940",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4465966-pfizers-covid-pill-shows-vaccine-profits-will-be-fleeting"
            }
        },
        {
            "id": "4464128",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-01T12:30:16-04:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310813998/image_1310813998.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Is A Strong Medium-Term Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105995",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "347339",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4464128-pfizer-strong-medium-term-buy"
            }
        },
        {
            "id": "4461819",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-25T13:51:39-04:00",
                "isLockedPro": false,
                "commentCount": 99,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251485261/image_1251485261.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Vs. Pfizer: Which Healthcare Stock Is The Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "346327",
                            "type": "sentiment"
                        },
                        {
                            "id": "346328",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4461819-merck-vs-pfizer-healthcare-stock-better-buy"
            }
        },
        {
            "id": "4461652",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-24T06:24:52-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1266187248/image_1266187248.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: It Might Be Time To Buy The Dip",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "346231",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4461652-global-blood-therapeutics-buy-the-dip-gbt-stock"
            }
        },
        {
            "id": "4461616",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-23T10:27:03-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Apple Earnings, Facebook Talks Metaverse And GlobalFoundries IPO",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4461616-stocks-to-watch-apple-earnings-facebook-talks-metaverse-and-globalfoundries-ipo"
            }
        },
        {
            "id": "4460919",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-20T16:44:46-04:00",
                "isLockedPro": false,
                "commentCount": 110,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1235266661/image_1235266661.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "COVID Vaccine Is Not A Non-Event For Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "345789",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4460919-covid-vaccine-is-not-a-non-event-for-pfizer"
            }
        },
        {
            "id": "4460344",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-18T08:17:11-04:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Is An Asymmetric Growth Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106337",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "345416",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4460344-pfizer-pfe-stock-asymmetric-growth-opportunity"
            }
        },
        {
            "id": "4459846",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-14T08:44:56-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1293518316/image_1293518316.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Arena Pharmaceuticals: A Speculative Buy To Play The Upcoming Etrasimod's Data-Readout",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105808",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "344989",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4459846-arena-pharmaceutical-a-speculative-buy"
            }
        },
        {
            "id": "4459346",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-11T11:47:32-04:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1229555002/image_1229555002.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Pfizer Stock A Buy Or Sell After Booster Shot Authorization?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "344474",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4459346-pfizer-stock-buy-sell-booster"
            }
        },
        {
            "id": "4459015",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-08T08:20:25-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227739745/image_1227739745.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "News From New Zealand Makes Pfizer A Buy For 2022 And Beyond",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105950",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "344326",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4459015-news-from-new-zealand-makes-pfizer-a-buy-for-2022-and-beyond"
            }
        },
        {
            "id": "4458997",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-08T05:43:59-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1302365594/image_1302365594.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Lackluster With No Significant Booster Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103738",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "344314",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4458997-pfizer-lackluster-with-no-significant-booster-growth"
            }
        },
        {
            "id": "4454292",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-09T12:57:06-04:00",
                "isLockedPro": false,
                "commentCount": 59,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1298099790/image_1298099790.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Vs. BioNTech Stock: Which Is The Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "340737",
                            "type": "sentiment"
                        },
                        {
                            "id": "340738",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4454292-pfizer-vs-biontech-stock-better-buy"
            }
        },
        {
            "id": "4453883",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-07T11:09:19-04:00",
                "isLockedPro": false,
                "commentCount": 130,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1285261108/image_1285261108.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's 3CL Protease Inhibitor May Cut The Achilles' Heel Of COVID-19",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105156",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "340066",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4453883-pfizer-antiviral-may-cut-the-achilles-heel-of-covid-19"
            }
        },
        {
            "id": "4453034",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-01T13:14:05-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288428941/image_1288428941.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Vaccine Outperformance Propels For The Long Run",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106245",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "339830",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4453034-pfizer-outperformance-propels-for-long-run"
            }
        },
        {
            "id": "4453013",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-01T12:00:33-04:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297820501/image_1297820501.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Vs. Moderna Stock: Which Is The Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "339852",
                            "type": "sentiment"
                        },
                        {
                            "id": "339838",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4453013-pfizer-vs-moderna-stock-better-buy"
            }
        },
        {
            "id": "4452569",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-30T10:28:54-04:00",
                "isLockedPro": false,
                "commentCount": 52,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440976/image_1292440976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons Why Pfizer Stock Is A Buy At All-Time Highs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104783",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "339546",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4452569-3-reasons-why-pfizer-stock-is-a-buy-at-all-time-highs"
            }
        },
        {
            "id": "4449581",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-15T19:12:06-04:00",
                "isLockedPro": false,
                "commentCount": 78,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440976/image_1292440976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer And Merck: Two Long-Term Laggards In A Momentum Market, As Pfizer Gets A Catalyst From Covid-19",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "337534",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4449581-pfizer-and-merck-two-long-term-laggards-in-a-momentum-market-as-pfizer-gets-a-catalyst-from-covid-19"
            }
        },
        {
            "id": "4446328",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-07T03:43:46-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1280727099/image_1280727099.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Attempting To Classify The Investment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "336395",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4446328-global-blood-therapeutics-attempting-to-classify-the-investment"
            }
        },
        {
            "id": "4442627",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-29T13:50:00-04:00",
                "isLockedPro": false,
                "commentCount": 110,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1262577719/image_1262577719.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Pfizer Is One Of My Largest Positions",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59101",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "335144",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4442627-pfizer-stock-one-of-my-largest-positions"
            }
        },
        {
            "id": "4441419",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-26T13:10:07-04:00",
                "isLockedPro": false,
                "commentCount": 227,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227739745/image_1227739745.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer/BioNTech COVID Vaccine(s) And The Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "334640",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4441419-pfizerbiontech-covid-vaccines-and-the-future"
            }
        },
        {
            "id": "4441178",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-24T09:42:48-04:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Apple And Tesla Lead Earnings Blitz, New IPOs And SPAC Debuts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4441178-stocks-to-watch-apple-and-tesla-lead-earnings-blitz-new-ipos-and-spac-debuts"
            }
        },
        {
            "id": "4439978",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-19T16:55:45-04:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186300103/image_186300103.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: The Wildcard",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "66353",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "333747",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4439978-pfizer-stock-pfe-the-wildcard"
            }
        },
        {
            "id": "4438724",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-12T01:09:27-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288428941/image_1288428941.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Shares Likely To Get A Boost In The Second Half Of 2021",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "332708",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4438724-pfizer-shares-likely-to-get-a-boost-in-second-half"
            }
        },
        {
            "id": "4438614",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-11T02:27:02-04:00",
                "isLockedPro": false,
                "commentCount": 226,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297221800/image_1297221800.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: mRNA Vaccines Not A Flash In The Pan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "332631",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4438614-pfizer-mrna-vaccines-not-a-flash-in-the-pan"
            }
        },
        {
            "id": "4436816",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-27T15:10:44-04:00",
                "isLockedPro": false,
                "commentCount": 73,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291860619/image_1291860619.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend Sleuthing: Pfizer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40591",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "331076",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4436816-dividend-sleuthing-pfizer"
            }
        },
        {
            "id": "4436339",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-24T08:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1296010631/image_1296010631.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Pfizer Stock Still A Buy In 2021? For The Right Investors, Yes",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "330557",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4436339-pfizer-stock-buy-2021"
            }
        },
        {
            "id": "4436314",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-24T01:06:12-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1299632068/image_1299632068.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: A Wide Moat Business At A Fair Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "330547",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4436314-pfizer-wide-moat-business-fair-price"
            }
        },
        {
            "id": "4436245",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-23T13:05:38-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227739745/image_1227739745.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Serendipity, Pfizer And A Value Investment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31951",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "330476",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4436245-serendipity-pfizer-stock-pfe-value-investment"
            }
        },
        {
            "id": "4436153",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-23T10:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303673696/image_1303673696.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Fully Vaccinated",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103738",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "330470",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4436153-pfizer-fully-vaccinated"
            }
        },
        {
            "id": "4432124",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-30T11:00:57-04:00",
                "isLockedPro": false,
                "commentCount": 160,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288428941/image_1288428941.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: mRNA COVID Vaccine Is Transforming And More To Come",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "327388",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4432124-pfizer-mrna-covid-vaccine-huge-transformative-potential"
            }
        },
        {
            "id": "4430669",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-23T08:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 142,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1298099807/image_1298099807.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer's New Vaccine Golden Goose Makes It A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "50452",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "326387",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4430669-pfizer-stock-buy-on-vaccine-windfall"
            }
        },
        {
            "id": "4430369",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-21T03:10:19-04:00",
                "isLockedPro": false,
                "commentCount": 124,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1200706447/image_1200706447.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Connecting The Dots: Are Pfizer And Arvinas At Work On A COVID Cure?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "46471",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "324240",
                            "type": "sentiment"
                        },
                        {
                            "id": "324239",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4430369-connecting-the-dots-are-pfizer-and-arvinas-at-work-on-a-covid-cure"
            }
        },
        {
            "id": "4427544",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-11T16:27:41-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/530818462/image_530818462.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Stock Forecast: How To View Q1 Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104812",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "324862",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4427544-pfizer-stock-forecast-q1-earnings"
            }
        },
        {
            "id": "4426526",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-09T14:25:09-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196621604/image_1196621604.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Increasing Specialization In SCD",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56582",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "324635",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4426526-global-blood-therapeutics-increasing-specialization-in-scd"
            }
        },
        {
            "id": "4426396",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-09T08:44:51-04:00",
                "isLockedPro": false,
                "commentCount": 222,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1224202684/image_1224202684.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Or Bristol-Myers Squibb: Which Is A Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102896",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "324569",
                            "type": "sentiment"
                        },
                        {
                            "id": "324570",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4426396-pfizer-or-bristol-myers-squibb-which-is-a-better-buy"
            }
        },
        {
            "id": "4425933",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-08T07:22:28-04:00",
                "isLockedPro": false,
                "commentCount": 84,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288428941/image_1288428941.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Is Increasingly Attractive - With Or Without The Vaccine",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102214",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "324371",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4425933-pfizer-is-increasingly-attractive-without-vaccine"
            }
        },
        {
            "id": "4425911",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-08T03:46:57-04:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227739745/image_1227739745.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Offers An Attractive Risk-Return Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "324457",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4425911-pfizer-offers-an-attractive-risk-return-opportunity"
            }
        },
        {
            "id": "4421064",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-24T09:34:19-04:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Apple, Tesla And Microsoft Lead Huge Earnings Week",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4421064-stocks-to-watch-apple-tesla-and-microsoft-lead-huge-earnings-week"
            }
        },
        {
            "id": "4420227",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-21T08:59:17-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1217640102/image_1217640102.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Sell-Off Alters My Investment Strategy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "322093",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4420227-global-blood-therapeutics-gbt-stock-sell-off-alters-investment-strategy"
            }
        },
        {
            "id": "4418651",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-12T12:15:10-04:00",
                "isLockedPro": false,
                "commentCount": 75,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1287045622/image_1287045622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Monumental Share Float Flattens Growth Prospects",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "320921",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4418651-pfizer-monumental-share-float-flattens-pfizers-growth-prospects"
            }
        },
        {
            "id": "4417793",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-06T08:44:47-04:00",
                "isLockedPro": false,
                "commentCount": 112,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253358164/image_1253358164.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Why It's An Easy High Conviction Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59101",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "320072",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4417793-pfizer-stock-high-conviction-buy"
            }
        },
        {
            "id": "4417708",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-06T07:45:00-04:00",
                "isLockedPro": false,
                "commentCount": 57,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1230145101/image_1230145101.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: COVID Vaccine And Beyond",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "319239",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4417708-pfizer-covid-vaccine-and-beyond"
            }
        },
        {
            "id": "4417737",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-05T23:04:35-04:00",
                "isLockedPro": false,
                "commentCount": 112,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Offers Investors An 18% To 100% Return",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101430",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "319878",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4417737-pfizer-offers-investors-18-to-100-percent-return"
            }
        },
        {
            "id": "4417655",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-05T12:53:50-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227739745/image_1227739745.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pharmaceutical Company Pfizer Dividend Growth Investing Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102592",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "320003",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4417655-pfizer-dividend-growth-investing-results"
            }
        },
        {
            "id": "4415526",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-23T07:03:38-04:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291860619/image_1291860619.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Ultra-Cold Storage Of COVID-19 Vaccine No Longer Required",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "318279",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4415526-pfizer-ultra-cold-storage-of-covidminus-19-vaccine-no-longer-required"
            }
        },
        {
            "id": "4414168",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-16T02:46:37-04:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Forget About Momentum And Start Buying Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78125",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "317156",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4414168-pfizer-forget-momentum-and-start-buying-value"
            }
        },
        {
            "id": "4413689",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-13T09:16:00-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Nike, FedEx, Rising Yield Plays And A Sports ETF",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4413689-stocks-to-watch-nike-fedex-rising-yield-plays-and-a-sports-etf"
            }
        },
        {
            "id": "4411363",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-04T11:34:26-05:00",
                "isLockedPro": false,
                "commentCount": 74,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Has A Unique Portfolio Outside Of Its Vaccine",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "315853",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4411363-pfizer-unique-portfolio-outside-of-vaccine"
            }
        },
        {
            "id": "4408976",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-25T13:26:31-05:00",
                "isLockedPro": false,
                "commentCount": 52,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Forget Pfizer Stock, Buy Historically Cheap Call Options",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104907",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "314857",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4408976-pfizer-stock-buy-historically-cheap-call-options"
            }
        },
        {
            "id": "4408827",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-25T00:47:43-05:00",
                "isLockedPro": false,
                "commentCount": 86,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "COVID-19 Continues, But Good Times For mRNA Vaccine Developers Pfizer/BioNTech And Moderna",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "314791",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4408827-covid-19-continues-but-good-times-for-mrna-vaccine-developers-pfizer-biontech-moderna"
            }
        },
        {
            "id": "4408574",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-24T13:05:55-05:00",
                "isLockedPro": false,
                "commentCount": 324,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "12 Reasons Novavax Beats Pfizer For Titles Of Best Covid Vaccine And Best Covid Vaccine Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "99786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "314287",
                            "type": "sentiment"
                        },
                        {
                            "id": "314288",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4408574-12-reasons-novavax-beats-pfizer-for-titles-of-best-covid-vaccine-and-best-covid-vaccine-stock"
            }
        },
        {
            "id": "4404303",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-11T09:31:00-05:00",
                "isLockedPro": false,
                "commentCount": 119,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Buy It For A Safe 4% Plus Dividend Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "312409",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4404303-pfizer-buy-for-safe-4-percent-plus-dividend-yield"
            }
        },
        {
            "id": "4404923",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-10T12:40:17-05:00",
                "isLockedPro": false,
                "commentCount": 82,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Look For A Bounce In Pfizer After 2-Month Pullback",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106067",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "312185",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4404923-pfizer-look-for-bounce-after-two-month-pullback"
            }
        },
        {
            "id": "4404278",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-08T10:32:22-05:00",
                "isLockedPro": false,
                "commentCount": 51,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Fundamentals Point To Higher Prices",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "312421",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4404278-pfizer-fundamentals-point-to-higher-prices"
            }
        },
        {
            "id": "4404261",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-08T09:42:26-05:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Celebrity Status At Attractive Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102214",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "312386",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4404261-pfizer-celebrity-status-attractive-value"
            }
        },
        {
            "id": "4400500",
            "type": "article",
            "attributes": {
                "publishOn": "2021-01-22T16:09:10-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Global Blood Therapeutics: Ready To Face A Promising Year In 2021",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "51702",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "309148",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4400500-global-blood-therapeutics-ready-to-face-promising-year-in-2021"
            }
        },
        {
            "id": "4399482",
            "type": "article",
            "attributes": {
                "publishOn": "2021-01-18T09:05:56-05:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Weak Full-Year Earnings Estimate Hurts The Bull Case",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "309303",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4399482-pfizer-weak-full-year-earnings-estimate-hurts-bull-case"
            }
        },
        {
            "id": "4397671",
            "type": "article",
            "attributes": {
                "publishOn": "2021-01-06T21:12:28-05:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer: Mr. Market Vs. The Analysts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "307798",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1216",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4397671-pfizer-mr-market-vs-analysts"
            }
        }
    ]
}